These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Slowly Signaling G Protein-Biased CB Lin X; Dhopeshwarkar AS; Huibregtse M; Mackie K; Hohmann AG Mol Pharmacol; 2018 Feb; 93(2):49-62. PubMed ID: 29192123 [TBL] [Abstract][Full Text] [Related]
7. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Deng L; Guindon J; Vemuri VK; Thakur GA; White FA; Makriyannis A; Hohmann AG Mol Pain; 2012 Sep; 8():71. PubMed ID: 22998838 [TBL] [Abstract][Full Text] [Related]
8. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127 [TBL] [Abstract][Full Text] [Related]
11. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. Rahn EJ; Zvonok AM; Thakur GA; Khanolkar AD; Makriyannis A; Hohmann AG J Pharmacol Exp Ther; 2008 Nov; 327(2):584-91. PubMed ID: 18664590 [TBL] [Abstract][Full Text] [Related]
12. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Lin X; Xu Z; Carey L; Romero J; Makriyannis A; Hillard CJ; Ruggiero E; Dockum M; Houk G; Mackie K; Albrecht PJ; Rice FL; Hohmann AG Pain; 2022 May; 163(5):834-851. PubMed ID: 35001054 [TBL] [Abstract][Full Text] [Related]
14. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915 [TBL] [Abstract][Full Text] [Related]
15. Positive Allosteric Modulation of CB Slivicki RA; Iyer V; Mali SS; Garai S; Thakur GA; Crystal JD; Hohmann AG Front Mol Neurosci; 2020; 13():54. PubMed ID: 32410959 [TBL] [Abstract][Full Text] [Related]
16. Chemogenetic Regulation of CX3CR1-Expressing Microglia Using Gi-DREADD Exerts Sex-Dependent Anti-Allodynic Effects in Mouse Models of Neuropathic Pain. Saika F; Matsuzaki S; Kobayashi D; Ideguchi Y; Nakamura TY; Kishioka S; Kiguchi N Front Pharmacol; 2020; 11():925. PubMed ID: 32636748 [TBL] [Abstract][Full Text] [Related]
17. Modulating the endocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies. O'Hearn S; Diaz P; Wan BA; DeAngelis C; Lao N; Malek L; Chow E; Blake A Ann Palliat Med; 2017 Dec; 6(Suppl 2):S209-S214. PubMed ID: 29156899 [TBL] [Abstract][Full Text] [Related]
18. δ-Opioid receptors in primary sensory neurons tonically restrain nociceptive input in chronic pain but do not enhance morphine analgesic tolerance. Jin D; Chen H; Huang Y; Chen SR; Pan HL Neuropharmacology; 2022 Oct; 217():109202. PubMed ID: 35917874 [TBL] [Abstract][Full Text] [Related]
19. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Naguib M; Xu JJ; Diaz P; Brown DL; Cogdell D; Bie B; Hu J; Craig S; Hittelman WN Anesth Analg; 2012 May; 114(5):1104-20. PubMed ID: 22392969 [TBL] [Abstract][Full Text] [Related]
20. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]